BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Shares in Dexcom plunged in extended trading Thursday after the medical devices company ...

Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Looking into the current session, DexCom Inc. (NASDAQ:DXCM) shares are trading at $69.95, after a 0.09% increase. Moreover, over the past month, the stock spiked by 2.13%, but in the past year, fell ...

BTIG analyst Marie Thibault maintained a Buy rating on Dexcom on July 10 and set a price target of $80.00. The company’s shares closed yesterday at $74.96. TipRanks Welcomes a New ETF – NYSE:RANK ...

Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $92 from $113 and keeps an Equal Weight rating on the shares. The firm says its 2025 medical technology outlook “hinges ...

DexCom reported revenue of $1.21 billion in the third quarter, up 22% year over year, with U.S. revenue growing by 21% and international revenue growing by 22%. Adjusted net income was $0.61 per share ...